This site uses cookies to simplify and improve your online experience.  You can find out more about cookies and how you can disable them by reading our Terms and Conditions. By continuing to browse this site you agree to our use of cookies on this device.

Roche Navigation Menu Roche Resources : Roche Resources
  • Sign in
  • Logout
  • Search
Roche
  • Up
  • Home
  • Search
  • Close search

						
							

Searching

    • Home
    • Roche Medicines
      Roche Medicines Overview
      • Oncology
      • Alecensa®▼(alectinib)
      • Kadcyla® (trastuzumab emtansine)
      • PERJETA® (pertuzumab)
      • PHESGO®▼ (pertuzumab/trastuzumab)
      • TECENTRIQ®▼ (atezolizumab)
      • Rozlytrek®▼(entrectinib)
      • Neuroscience
      • OCREVUS®▼ (ocrelizumab)
      • Haematology
      • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
      • Evrysdi®▼ (risdiplam)
      • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      Therapy Areas Overview
      • Oncology
      • Breast Cancer
      • Haematology
      • Haematology
      • Neuroscience
      • Neuroscience
    • Congress and Meetings
      Congress and Meetings Overview
    • HCP Materials
      HCP Materials Overview
    • FAQs
      FAQs Overview
    • Prescribing Information
      Prescribing Information Overview
      • Find out more about:
      • ALECENSA®▼(alectinib) Great Britain
      • ALECENSA® (alectinib) Northern Ireland
      • Avastin® (bevacizumab) [Great Britain]
      • Avastin (bevacizumab) [Northern Ireland]
      • Evrysdi®▼(risdiplam)
      • GAZYVARO® (obinutuzumab) Great Britain
      • GAZYVARO® (obinutuzumab) Northern Ireland
      • HEMLIBRA®▼(emicizumab) Great Britain
      • HEMLIBRA®▼(emicizumab) Northern Ireland
      • Herceptin® (trastuzumab) IV
      • Herceptin® (trastuzumab) SC
      • Kadcyla® (trastuzumab emtansine)
      • OCREVUS®▼ (ocrelizumab) GB
      • OCREVUS®▼ (ocrelizumab) NI
      • Perjeta® (pertuzumab)
      • Phesgo®▼(pertuzumab/trastuzumab)
      • Polivy®▼(polatuzumab vedotin) Great Britain
      • Polivy®▼(polatuzumab vedotin) Northern Ireland
      • Rozlytrek® ▼(entrectinib)
      • TECENTRIQ®▼ (atezolizumab) Great Britain
      • Tecentriq® (atezolizumab) Northern Ireland
    • Adverse Event Reporting
      Adverse Event Reporting Overview
    • Home
    • Roche Medicines
      • Oncology
        • Alecensa®▼(alectinib)
        • Kadcyla® (trastuzumab emtansine)
        • PERJETA® (pertuzumab)
        • PHESGO®▼ (pertuzumab/trastuzumab)
        • TECENTRIQ®▼ (atezolizumab)
        • Rozlytrek®▼(entrectinib)
      • Neuroscience
        • OCREVUS®▼ (ocrelizumab)
      • Haematology
        • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
        • Evrysdi®▼ (risdiplam)
        • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      • Oncology
        • Breast Cancer
      • Haematology
        • Haematology
      • Neuroscience
        • Neuroscience
    • Congress and Meetings
    • HCP Materials
    • FAQs
    • Prescribing Information
      • Find out more about:
        • ALECENSA®▼(alectinib) Great Britain
        • ALECENSA® (alectinib) Northern Ireland
        • Avastin® (bevacizumab) [Great Britain]
        • Avastin (bevacizumab) [Northern Ireland]
        • Evrysdi®▼(risdiplam)
        • GAZYVARO® (obinutuzumab) Great Britain
        • GAZYVARO® (obinutuzumab) Northern Ireland
        • HEMLIBRA®▼(emicizumab) Great Britain
        • HEMLIBRA®▼(emicizumab) Northern Ireland
        • Herceptin® (trastuzumab) IV
        • Herceptin® (trastuzumab) SC
        • Kadcyla® (trastuzumab emtansine)
        • OCREVUS®▼ (ocrelizumab) GB
        • OCREVUS®▼ (ocrelizumab) NI
        • Perjeta® (pertuzumab)
        • Phesgo®▼(pertuzumab/trastuzumab)
        • Polivy®▼(polatuzumab vedotin) Great Britain
        • Polivy®▼(polatuzumab vedotin) Northern Ireland
        • Rozlytrek® ▼(entrectinib)
        • TECENTRIQ®▼ (atezolizumab) Great Britain
        • Tecentriq® (atezolizumab) Northern Ireland
    • Adverse Event Reporting
    • Sign in
    • Logout
    Close

    1 - of results for ""

    No results

    This website is intended for healthcare professionals (HCPs) only. If you are an HCP, register free to access the full content.

    • How to use

      Read more

    • TECENTRIQ®▼ (atezolizumab)
    • HCC
      • Efficacy
      • QoL
      • Safety
      • MOA
      • Study design
    • NSCLC
      • Efficacy
      • Safety
      • How to Use
    • eNSCLC
    • More
      • HCC
      • NSCLC
      • eNSCLC

    You are here:

    1. Roche Medicines
    2. Oncology
    3. TECENTRIQ®▼ (atezolizumab)
    4. HCC
    5. How to use

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.

    Prescribing Information

    TECENTRIQ®▼(atezolizumab) Great Britain
    TECENTRIQ®▼ (atezolizumab) Northern Ireland
    Avastin (bevacizumab) Great Britain
    Avastin (bevacizumab) Northern Ireland

    Adverse event reporting and additional monitoring

    How to use TECENTRIQ + Avastin for the first-line systemic treatment of adult patients with advanced or unresectable HCC1,2

    Considerations before starting

    > More

    Dosing and administration

    > More

    Managing AEs

    > More

    Risk management materials

    > More

    Considerations before starting1-3

    • Oesophageal varices should be screened for and subsequently treated as per clinical practice
    • Pre-existing hypertension should be adequately controlled
    • Carefully consider the risk of aneurysms and/or artery dissections in patients with risk factors such as hypertension or history of aneurysm
    • AST, ALT, bilirubin, thyroid function, proteinuria by dipstick urinalysis, blood glucose and renal function should be monitored
    • Consider appropriate management of patients with abnormal thyroid function tests at baseline
    • The use of systemic corticosteroids or immunosuppressants before starting treatment should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of TECENTRIQ
    • Avastin should not be initiated for at least 28 days following major surgery or until the surgical wound is fully healed 
    • Fertility preservation strategies should be discussed with women of child-bearing potential because Avastin may impair female fertility
    • Consider a dental examination and appropriate preventive dentistry because invasive dental procedures are a risk factor for osteonecrosis of the jaw in patients on Avastin
    • Refer to the TECENTRIQ and Avastin SmPCs for details of contraindications, warnings and precautions

    Dosing and administration1–4

    Eligible patients should be administered treatment infusions every 3 weeks as follows:

    Other dosing schedules are available, for more information please see the smpc

    • Treatment should continue until loss of clinical benefit or unmanageable toxicity
    • Dose reduction for adverse reactions is not recommended. If indicated, therapy should either be permanently discontinued or temporarily suspended

    See the outcomes that could be achieved with TECENTRIQ + Avastin

    Managing AEs1,2

    Most immune-related AEs occurring during TECENTRIQ treatment are reversible with appropriate management

    • Most immune-related AEs were reversible with interruptions of TECENTRIQ and initiation of corticosteroids and/or supportive care
    • For suspected immune-related AEs, thorough evaluation to confirm aetiology or exclude other causes should be performed
    • Based on the severity of the AE, TECENTRIQ should be withheld and corticosteroids administered
    • Once improved to grade ≤1, corticosteroids should be tapered over ≥1 month*
    • TECENTRIQ must be permanently discontinued for any grade 3 immune-related AE that recurs and for any grade 4 immune-related AE, except for endocrinopathies that are controlled with replacement hormones

    *Based on limited data from clinical studies in patients whose immune-related adverse reactions could not be controlled with systemic corticosteroid use, other systemic immunosuppressants may be considered.

    View the safety profile of TECENTRIQ + Avastin

    Management guidance for TECENTRIQ-related AEs1,2

    • Pneumonitis
    • Hepatitis
    • Colitis or diarrhoea
    • Hypothyroidism
    • Hyperthyroidism
    • Adrenal insufficiency
    • Hypophysitis
    • Type 1 diabetes mellitus
    • Infusion-related reaction
    • Rash/Severe cutaneous adverse reactions
    • Myasthenic syndrome/myasthenia gravis, Guillain‑Barré syndrome and meningoencephalitis
    • Pancreatitis
    • Myocarditis
    • Nephritis
    • Myositis
    • Other immune-related adverse reaction

    Management guidance for Avastin-related AEs

    • Hypertension
    • Proteinuria
    • Haemorrhage
    • Thromboembolic events
    • GI perforation and fistulae
    • Wound healing
    • PRES
    • Hypersensitivity/infusion reactions

    Risk management materials to support you and your patients1,2

     

    • You must discuss the risks of TECENTRIQ therapy with your patients
    • Patients must be provided with the Tecentriq patient alert card, which forms part of the Risk Management Plan
    • Please contact Medical Information for risk management support regarding Avastin

    View the safety profile of TECENTRIQ + Avastin

     

    AE, adverse event; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CNS, central nervous system; GI, gastrointestinal; HCC, hepatocellular carcinoma; IV, intravenous; PRES, posterior reversible encephalopathy syndrome; SmPC, summary of product characteristics; ULN, upper limit of normal.

    References:

    1. Tecentriq Summary of Product Characteristics - Great Britain, Tecentriq Summary of Product Characteristics - Northern Ireland
    2. Avastin Summary of Product Characteristics - Great Britain, Avastin Summary of Product Characteristics - Northern Ireland
    3. Finn RS et al. N Engl J Med 2020;382:1894–1905.


    M-GB-00005810
    Date of preparation: December 2021.

    Welcome to Roche Resources

    Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

    I am a healthcare professional I am a member of the public
    • © 2022 Roche Products Limited
    • 01.07.2022
    • Terms and Conditions
    • Privacy Policy
    • Prescribing Information
    • Contact

    This is a promotional website intended for UK healthcare professionals, designed, built and funded by Roche Products Ltd. This website is intended to be viewed on a desktop/laptop. M-GB-00008047 Date of Preparation June 2022.